close

Aarti Drugs Ltd

Know More
NSEBSE

555.052.70 (0.49%)

02:39 PM,25th Sep 2023

553.651.50 (0.27%)

02:55 PM,25th Sep 2023

BSE : 524348

NSE : AARTIDRUGS

Sector : Health care

ISIN Code : INE767A01016

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Sep 25 2023 | 02:55 PM IST

Market Cap (₹ Cr)

5139

Turnover (₹ Cr)

0.69

Volume (Shares)

124047

Face Value

10

52-WK High

645.75

52-WK High Date

25 Jul 2023

52-WK Low

313.90

52-WK Low Date

20 Mar 2023

All Time High

1026.95

All Time High Date

08 Oct 2020

All Time Low

0.95

All Time Low Date

08 Dec 1997

Aarti Drugs Ltd

Aarti Drugs Limited (ADL) is a prominent manufacturer of APIs Pharma Intermediates and Specialty Chemicals. The Company operates as part of the Aarti Group a conglomerate with a net worth of USD 900 million. With over 50 compounds for Antibiotics Anti Protozoal Anti-Inflammatory Anti-diabetic Anti Fungal and Cardioprotectant therapeutic segments the Company has emerged as market leader in APIs. It has a wholly-owned subsidiary called Pinnacle Life Science Private Limited which operates in the field of manufacturing formulations. The Company has two R&D divisions one in Tarapur and the other in Turbhe Maharashtra. It has 3 subsidiaries namely Pinnacle Life Science Private Limited Aarti Speciality Chemicals Limited and Pinnacle Chile SpA (foreign subsidiary). Of the above subsidiaries Pinnacle Life Science Private Limited and Aarti Speciality Chemicals Limited are wholly owned subsidiaries.The manufacturing units of the Company are GMP certified. Their products include Active Pharmaceutical Ingredients (APIs) Steroids Pharmaceutical Intermediates and Specialty Chemicals such as Benzene Sulphonyl Chloride Benzene Sulphonic Acid/ Ammonium/ Sodium Salt and Benzene Sulphonamide. Aarti Drugs Ltd a part of Aarti Group of Industries was incorporated in September 28th 1984. In the year 1993 the company implemented the second phase of their backward integration project and set up facilities for glyoxal (the main raw material for imidazoles). During the year 1994-95 the company commissioned a plant to recover and market ammonium sulphate derived from plant effluents. Also Rupal Chemical Industries a group company was amalgamated with the company.During the year 1996-97 the company started their production of secnidazole and dichlofenac sodium. During the year 2000-01 they started the commercial production of Pharmaceutical Ingredients. During the year 2002-03 the company expanded the production capacity of bulk drugs by 598000 kg to 17430000 kg. During the year 2003-04 the company further expanded the production capacity of bulk drugs by 588000 kg to 18018000 kg. During the year 2004-05 the company started commercial production at their newly setup intermediate plant at Tarapur. During the year 2005-06 the company increased the production capacity of Pharmaceutical by 2325000 kg to 24020000 kg. They entered into joint venture with Chinese company engaged in Active Pharmaceutical Ingredients (APIs) manufacturing and formed Huanggang Yinhe Aarti Pharmaceutical Company Ltd for manufacturing and selling of APIs in China. Also they acquired controlling stake in Suyash Laboratories Ltd so as to make the said company a subsidiary of the company.During the year 2006-07 the company increased the production capacity by 570000 kg to 24590000 kg. During the next year they increased the production capacity by 399000 kg to 24989000 kg. During the year 2008-09 they further increased the production capacity of Pharmaceutical by 50000 kg to 25000000 kg.During the year 2009-10 the company carried out research and development work/ process improvement work in bulk drugs such as antihistaminic/anti-allergic anti-inflammatory and anti-diabetic. ADL has exported intermediates such as Stage-I of pioglitazone and AU-% for tamsulosin and have expanded the production capacity from 25000000 kg to 25716000 kg. A Scheme of Amalgamation of Suyash Laboratories Ltd. wholly owned subsidiary of the Company with the Company became operative w.e.f. from 1st April 2011 being the Appointed Date upon filing of High Court Order sanctioning the said Scheme with the Registrar of Companies on 6th July 2012.During year 2015 Company acquired 100% equity shares in Pinnacle Life Science Pvt. Ltd. situated at Baddi Himachal Pradesh. During the year 2020 Company incorporated 2 overseas Subsidiaries and 1 Domestic subsidiary Company. Pinnacle Chile SpA incorporated in Santiago Chile was established for marketing the formulation of drugs and participating in the tender and private market in Chile. Aarti Speciality Chemicals Limited (Wholly Owned Subsidiary) located in Mumbai was founded for carrying on the business of manufacturers producers processors buyers sellers importers exporters and/ or otherwise dealers in Speciality and other chemicals pharmaceuticals and drugs. During the year 2021 Pinnacle Life Science LLC Wholly Owned Subsidiary was wound up/ closed as said Company did not have any business activity.In 2022 the Company commissioned brownfield expansion of Speciality Chemical Plant at Tarapur which turned operational effective from May 2022.

Aarti Drugs Ltd - Key Fundamentals

PARAMETER VALUES
Market Cap (₹ Cr)

5139

EPS - TTM (₹) [S]

17.93

P/E Ratio (X) [S]

4.61

Face Value (₹) 10
Latest Dividend (%)10.00
Latest Dividend Date 08 Feb 2023
Dividend Yield (%) 0.18
Book Value Share (₹) [S]120.34
P/B Ratio (₹) [S]4.61
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)
DSP Small Cap Fund (IDCW) 198.10 3460817 1.64
DSP Small Cap Fund - Direct (IDCW) 198.10 3460817 1.64
DSP Small Cap Fund - Direct (G) 198.10 3460817 1.64
DSP Small Cap Fund (G) 198.10 3460817 1.64
DSP Healthcare Fund (G) 42.22 737671 2.57
DSP Healthcare Fund (IDCW) 42.22 737671 2.57
DSP Healthcare Fund - Direct (G) 42.22 737671 2.57
DSP Healthcare Fund - Direct (IDCW) 42.22 737671 2.57
DSP Value Fund (IDCW) 4.05 70785 0.61
DSP Value Fund - Direct (IDCW) 4.05 70785 0.61

Load more

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High

550.65

560.95

Week Low/High

550.00

605.00

Month Low/High

530.00

625.00

Year Low/High

313.90

646.00

All time Low/High

0.58

1027.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week-6.38%-6.45%-2.21-2.28%
1 Month3.10%3.12%1.872.12%
3 Month25.08%24.97%4.965.40%
6 Month43.81%43.57%14.9116.10%
1 Year18.71%18.79%13.7713.54%
3 Year-24.80%-24.77%76.8078.04%

Financials

Graph
Table

Bulk/ Block

ALL
NSE
BSE
ALL
BUY
SELL
DateClient NameExchangeTransactionQuantityPrice
25-07-2023GRAVITON RESEARCH CAPITAL LLPNSEBUY933060627.89
25-07-2023GRAVITON RESEARCH CAPITAL LLPNSESELL933060628.40
24-07-2023GRAVITON RESEARCH CAPITAL LLPNSESELL643754576.46
24-07-2023GRAVITON RESEARCH CAPITAL LLPNSEBUY643754575.88
24-07-2023NK SECURITIES RESEARCH PRIVATE LIMITEDNSEBUY553535588.25
24-07-2023NK SECURITIES RESEARCH PRIVATE LIMITEDNSESELL553535588.59
24-07-2023QE SECURITIESNSESELL505851587.73
24-07-2023QE SECURITIESNSEBUY497273587.77
24-03-2023GRAVITON RESEARCH CAPITAL LLPNSESELL723086395.54
24-03-2023GRAVITON RESEARCH CAPITAL LLPNSEBUY723086395.14

Load More

Peer Group Comparison

NamePrice(In Rs)Chg(%)Mkt Cap(Rs Cr)Sales(Rs Cr)Profit(Rs Cr)EPS(Rs)P/E(x)

Shareholding Pattern

Jun 2023
Archive
CategoryShare(%)
Promoter58.70
Financial Institutions Banks0.00
Foreign Institutional Investors1.96
Insurance Companies0.08
Mutual Funds Uti4.63
Other Institutional Investors0.01
Indian Public25.35
Others Non Institutional Investors9.27
Custodians0.00

Corporate Action

Announcement DatePurposeFromToRemarks
Data Not Found

Price History

Search for Price History

DateOpenHighLowCloseSharesTrades
Data Not Found

Load more

Company Info

Company Information

CMD & Executive Director : Prakash M Patil

ED / MD / Promoter : Rashesh C Gogri

ED / Joint MD / Promoter : Harshit M Savla

E D & Wholetime Director : Harit P Shah

WTD & Executive Director : Uday M Patil

Non Executive Director : Narendra Jagannath Salvi

Independent Non Exe. Director : Navin Chapshi Shah

Independent Non Exe. Director : Krishnacharya G Akamanchi

Independent Non Exe. Director : Priti Savla

Independent Non Exe. Director : Ankit Vikram Paleja

Independent Non Exe. Director : Bhaskar Narayan Thorat

Independent Non Exe. Director : Neha Gada

Registered Office: Plot No N-198 MIDC Tarapur, Pamtembhi Village Palghar Tal,Thane,Maharashtra-401506 Ph: 91-22-24072249

Email:investorrelations@aartidrugs.com

URL:http://www.aartidrugs.com